TAVI: Full one-year Evolut low-risk randomised results and economic implications
This Hot Line was presented at PCR e-Course 2020
Speaker:
M. Reardon
Summary
EVOLUT Low Risk Trial of self-expanding TAVI versus SAVR: discover the key take-aways from the economic analysis as well as the health economics implications to understand the potential drivers for TAVI cost-effectives in Europe.
Videos included on this page: the Hot Line presentation and an Investigator Perspective.
Full one-year Evolut low-risk randomised results and economic implications
Download presentation